Camzyos (mavacamten) Patient Assistance Program
Don’t let the high cost of brand cardiac myosin inhibitor disrupt your obstructive hypertrophic cardiomyopathy treatment. We help eligible patients access Camzyos (mavacamten capsules) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Camzyos (mavacamten) is FDA-approved to improve functional capacity and symptoms in adults with symptomatic NYHA class II–III obstructive hypertrophic cardiomyopathy (HCM). First-in-class cardiac myosin inhibitor — reduces cardiac hypercontractility and LVOT obstruction. Available only through a REMS program due to heart failure risk from systolic dysfunction. Requires echocardiographic monitoring.
- Without assistance, Camzyos costs commonly run approximately $9,000–$11,000 per month.
- Through AffordMyPrescriptions, qualifying patients can access Camzyos for a flat $69.95 per month.
- Other obstructive HCM therapies: beta-blockers (metoprolol, atenolol — generic; first-line), non-dihydropyridine calcium channel blockers (verapamil, diltiazem — generic), disopyramide (generic; adjunct), septal reduction therapy (surgical myectomy or alcohol septal ablation) for severe cases. Aficamten (Cytokinetics — under investigation) is a second cardiac myosin inhibitor in development. Camzyos is disease-modifying — targeting underlying myosin biology. Genetic testing considered. HCMA support and cardiology follow-up.
What is Camzyos Prescription Assistance Program?
The Camzyos Patient Assistance Program helps eligible patients access Camzyos for symptomatic obstructive HCM at little or no cost when meeting income, insurance, and clinical criteria. Free to apply, but requires detailed applications, cardiology coordination, echocardiography documentation, REMS enrollment, and ongoing renewal.
At AffordMyPrescriptions, our Patient Advocates handle the entire Camzyos PAP enrollment for a flat $69.95 per month — application, prescriber coordination, REMS documentation, refill management, and annual re-certification — so you never face a gap in your Camzyos HCM therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Camzyos enrollment — so you never face a gap in your obstructive hypertrophic cardiomyopathy treatment.
Pharmacy Price Comparison
- Without assistance, Camzyos costs thousands of dollars per month at specialty pharmacies. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Generic verapamil (alt) | ~$15/mo | Cheap symptomatic alt |
| Walgreens Specialty | ~$10,500/mo | Save substantially |
| CVS Specialty | ~$11,000/mo | Save substantially |
| Walmart Specialty | ~$9,500/mo | Save substantially |
| Specialty pharmacy | ~$9,000/mo | Save substantially |
| Generic beta-blocker (alt) | ~$10/mo | Cheap symptomatic alt |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Camzyos — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Camzyos Prescription Program?
The Camzyos Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Traditional HCM therapies (beta-blockers, verapamil, disopyramide — all generic and very cheap) are first-line and effective for many. Camzyos is transformative for patients with persistent symptoms despite optimization. HCM specialist and REMS enrollment are required.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Camzyos assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Camzyos is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Camzyos:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $9,000–$11,000 per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Camzyos assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Camzyos Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Camzyos:
Camzyos is the first-in-class cardiac myosin inhibitor — targeting the underlying molecular pathophysiology of hypertrophic cardiomyopathy by reducing cardiac hypercontractility. Available only through a REMS program due to heart failure risk from reduced left ventricular systolic function.
How It Works:
Hypertrophic cardiomyopathy (HCM) is characterized by inappropriate thickening of the left ventricle, often with left ventricular outflow tract (LVOT) obstruction causing symptoms (dyspnea, chest pain, syncope, exercise intolerance) and increasing risk of arrhythmias and sudden cardiac death. Traditional therapy (beta-blockers, calcium channel blockers, disopyramide) provides symptomatic relief but doesn’t address the underlying myosin biology. Mavacamten is a small molecule inhibitor of cardiac myosin ATPase — reducing the number of active actin-myosin cross-bridges and thus cardiac contractility. In HCM, it normalizes contractility, reduces the LVOT gradient, improves diastolic function, and provides symptomatic improvement — precision therapy targeting the molecular basis of disease.
Form and Use:
Camzyos capsules 2.5 mg, 5 mg, 10 mg, 15 mg. Starting dose 5 mg once daily. Titration based on echocardiographic LVOT gradient and left ventricular ejection fraction (LVEF). Maintenance 2.5–15 mg once daily. Requires echocardiogram before starting, at each titration, and periodically during maintenance. REMS-only prescribing.
Generic Availability:
No generic Camzyos. Aficamten (Cytokinetics — under investigation) is a second cardiac myosin inhibitor in late-stage development. Traditional HCM medical therapy (all generic): beta-blockers (metoprolol, atenolol — first-line, cheap), non-dihydropyridine CCBs (verapamil, diltiazem — cheap), disopyramide (adjunct with negative inotropy, cheap). Septal reduction therapy — surgical myectomy or alcohol septal ablation — for severe obstruction not responding to medical therapy. Genetic testing considered (family screening). Hypertrophic Cardiomyopathy Association (HCMA) provides patient resources. Cardiology and HCM specialty center follow-up.
Warnings:
Heart failure risk from systolic dysfunction (reduced LVEF — REMS program required; echocardiographic monitoring; hold or reduce dose if LVEF <50%), embryo-fetal toxicity (contraindicated in pregnancy), drug interactions (CYP2C19 and CYP3A4 substrate — strong inhibitors/inducers alter exposure significantly; contraindicated with strong CYP2C19 inhibitors, moderate CYP3A4 inhibitors, and strong CYP3A4 inducers). Other: dizziness, syncope, fatigue. REMS-only prescribing. Cardiology consultation and periodic echocardiogram essential. Discontinue before septal reduction procedures.
FAQ (Frequently Asked Questions)
How much does Camzyos cost without insurance?
$9,000–$11,000 per month at specialty pharmacy. Generic beta-blockers (metoprolol, atenolol) cost ~$4–$10 per month; generic verapamil and diltiazem are similarly cheap; generic disopyramide is ~$50–$100 per month.
How is Camzyos different from beta-blockers for HCM?
Camzyos is the first disease-modifying HCM therapy — targeting the underlying cardiac myosin biology. Beta-blockers, verapamil, and disopyramide provide symptomatic relief but don’t target the fundamental defect. Camzyos improves symptoms, functional capacity, and quality of life in patients with persistent symptoms despite optimized traditional therapy.
What is REMS and why does Camzyos require it?
Risk Evaluation and Mitigation Strategy — an FDA-required safety program. Camzyos can reduce heart contractility too much (systolic dysfunction), which can precipitate heart failure. REMS requires enrollment of prescribers, pharmacies, and patients; documented echocardiographic monitoring before and during therapy; and dose titration based on LVEF and outflow gradient.
Who is Camzyos for?
Adults with symptomatic NYHA class II–III obstructive HCM (LVOT obstruction). Requires echocardiographic confirmation of obstruction, adequate LVEF, and symptoms despite (or in place of) traditional therapy. Not currently for non-obstructive HCM. HCM specialist evaluation is recommended for selection.
Can Camzyos avoid the need for surgical procedures?
For many patients — yes. Some patients with severe obstruction historically required surgical myectomy or alcohol septal ablation. Camzyos provides an effective medical option that reduces the need for these invasive procedures in many patients — though procedures remain valuable for severe or refractory cases.
Take Control of Your Medication Costs
HCM disease-modifying therapy can transform quality of life. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.